XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Revenues:        
Revenue, net $ 37,140 $ 17,052 $ 95,865 $ 33,904
Operating expenses:        
Cost of revenues 3,668 3,586 11,148 8,953
Research and development (includes $7,475 and $6,888 of share-based compensation expense for the three months ended December 31, 2023 and 2022 and $24,305 and $26,548 for the nine months ended December 31, 2023 and 2022, respectively) 123,717 125,533 380,834 393,358
Acquired in-process research and development 0 97,749 26,450 97,749
Selling, general and administrative (includes $46,944 and $50,741 of share-based compensation expense for the three months ended December 31, 2023 and 2022 and $128,445 and $165,771 for the nine months ended December 31, 2023 and 2022, respectively) 197,282 168,261 517,827 474,996
Total operating expenses 324,667 395,129 936,259 975,056
Gain on sale of Telavant net assets 5,348,410 0 5,348,410 0
Income (loss) from operations 5,060,883 (378,077) 4,508,016 (941,152)
Change in fair value of investments 10,467 (25,948) 63,880 53,277
Change in fair value of debt and liability instruments 9,331 62,360 85,376 90,032
Gain on deconsolidation of subsidiaries 0 (12,514) (17,354) (29,276)
Interest income (31,953) (10,249) (62,967) (17,900)
Interest expense 9,444 8,446 27,603 19,393
Other income, net (34,743) (18,095) (33,405) (11,060)
Net income (loss) before income taxes 5,098,337 (382,077) 4,444,883 (1,045,618)
Income tax expense 25,672 2,819 31,181 8,983
Net income (loss) 5,072,665 (384,896) 4,413,702 (1,054,601)
Net loss attributable to noncontrolling interests (23,519) (32,882) (86,339) (79,188)
Net income (loss) attributable to Roivant Sciences Ltd. $ 5,096,184 $ (352,014) $ 4,500,041 $ (975,413)
Net income (loss) per common share:        
Net income (loss) per common share - basic (in dollars per share) $ 6.37 $ (0.49) $ 5.79 $ (1.39)
Net income (loss) per common share - diluted (in dollars per share) $ 6.03 $ (0.49) $ 5.46 $ (1.39)
Weighted average shares outstanding:        
Weighted average shares outstanding, basic (in shares) 800,587,716 713,319,399 776,759,728 703,054,773
Weighted average shares outstanding, diluted (in shares) 844,461,685 713,319,399 824,310,013 703,054,773
Product Revenue, Net [Member]        
Revenues:        
Revenue, net $ 20,666 $ 9,244 $ 55,749 $ 14,354
License, Milestone and Other Revenue [Member]        
Revenues:        
Revenue, net $ 16,474 $ 7,808 $ 40,116 $ 19,550